Global Anemia Treatment Drugs Market to Post a CAGR of 16.4% during 2018-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Anemia Treatment Drugs Market Size, Market Share, Application Analysis,
Regional Outlook, Growth Trends, Key Players, Competitive Strategies and
Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s
offering.

The Anemia Treatment Drugs market was valued at USD 23,155.8 Mn in 2017
and is expected to grow at a CAGR of 16.4% during the forecast period
2018 to 2026.

Market Insights

According to the American Society of Hematology, anemia is the most
common hematological disorder and affects more than 3 million Americans
every year. The global scenario is more concerning because the World
Health Organization states that globally around 1.62 billion people get
affected by anemia, which is equal to 22.5% of the global population. In
addition to that highest prevalence of anemia was found in the
preschool-age children, and the lowest prevalence is in men.

Furthermore, the highest number of individuals affected with anemia
after pre-school-age children are non-pregnant women which are around
31.2% of the total anemic population. The treatment specifically depends
on the type of anemia and other complications associated with it.
Currently, the treatment for anemia specifically focuses on supplements
and chronic conditions are directly treated with blood transfusion, stem
cell transplant or bone marrow transplant.

The major types of anemia that are treated with drugs are Iron
deficiency anemia, thalassemia, aplastic anemia, hemolytic anemia,
sickle cell anemia, and pernicious anemia. In the year 2017, iron
deficiency anemia and sickle cell anemia dominated the market together
accounting for nearly 60% of the market share. The key factors
responsible for the growth of these two types of anemia are sickle cell
anemia & aplastic anemia has the highest prevalence, and the available
drug treatment costs more compared to other types. These two types of
anemia are expected to maintain their dominance throughout the forecast
period due to the expected market entry of more than 10 molecules during
the forecast period from 2018 to 2026.

The anemia treatment drugs market comprises drugs such as vitamins &
iron supplements, antibiotics, immunosuppressant, bone marrow
stimulants, corticosteroids, gene therapy & iron chelating agents. In
2017, immunosuppressant & corticosteroids accounted for a combined
market share of 58% due to key market driving factors such as the rising
prevalence of anemia, increasing awareness related to anemia with the
initiative of government & non-government organizations, and incessant
advancement in the research & development of anemia treatment industry.

The drug pipeline of anemia treatment is very strong and several
prominent players are present along with their promising molecules. The
most efficient molecules present in the drug pipeline are
FG-4592/roxadustat (FibroGen), Daprodustat/GSK1278863 (GlaxoSmithKline),
Molidustat/BAY85-3934 (Bayer), Rivipansel (Pfizer), Luspatercept
(Celgene), OMS721 (Omeros Corporation), and LentiGlobin BB305 (bluebird
bio). Thus, such as strong drug pipeline is expected to drive the
overall anemia treatment drugs market significantly throughout the
forecast period.

Market Competition Assessment

The anemia treatment drugs market is expected to grow significantly in
the near future and there are several companies operating in this market
and expected to enter the market. The overall competitive scenario is
expected to observe a paradigm shift towards gene therapy & monoclonal
antibody therapies.

The key players present in this market are Pfizer, Inc., Amgen, Inc.,
Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen
Pharmaceutical, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc,
Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc.
among others.

Key Market Movements

• An increasing prevalence of anemia and its types in developed as well
  as developing countries
• Rising awareness in developing countries due to initiative and
  programs introduced by the government and non-government organizations
• Incessant development in the field of research and development in
  anemia treatment
• The major competition for the available drugs is from stem cell
  transplantation and upcoming pipeline drugs in the near future

Topics Covered

Chapter 1. Preface

1.1. Report Scope and Description

1.2. Research Methodology

Chapter 2. Executive Summary

2.1. Global Anemia Treatment Drugs Market Portraiture

2.2. Global Anemia Treatment Drugs Market, by Type of Anemia, 2017 (US$
Mn)

2.3. Global Anemia Treatment Drugs Market, by Type of Drug, 2017 (US$ Mn)

2.4. Global Anemia Treatment Drugs Market, by Geography, 2017 Vs 2026
(Value %)

Chapter 3. Global Anemia Treatment Drugs Market: Market Dynamics
and Future Outlook

3.1. Market Overview

3.2. Drivers

3.2.1. Rising prevalence of anemia and complications related with
diseases related to anemia

3.2.2. Increasing awareness related to anemia diagnosis and treatment
especially in developing and under developed countries from Asia, Africa
& South America

3.3. Challenges

3.3.1. Chronic anemia is treated with bone marrow transplantation or
blood transfusion there no drug treatment available in the market

3.4. Opportunities

3.4.1. Strong pipeline with number of promising molecules that will
drive the overall anemia treatment drugs market in the near future

3.5. Attractive Investment Proposition, by Geography, 2017

3.6. Competitive Landscape

3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Anemia Treatment Drugs Market, by Type of
Anemia, 2016 – 2026 (US$ Mn)

4.1. Overview

4.2. Iron deficiency anemia

4.3. Thalassemia

4.4. Aplastic anemia

4.5. Hemolytic anemia

4.6. Sickle cell anemia

4.7. Pernicious anemia

Chapter 5. Global Anemia Treatment Drugs Market, by Type of
Drug, 2016 – 2026 (US$ Mn)

5.1. Overview

5.2. Supplements

5.3. Antibiotics

5.4. Immunosuppresants

5.5. Bone Marrow Stimulants

5.6. Corticosteroids

5.7. Gene Therapy

5.8. Iron Chelating Agents

5.9. Pipeline Analysis: Global Anemia Treatment Drugs Market

5.9.1. Overview

5.9.2. Phase III Drugs: Market Size Forecast till 2026 (US$ Mn)

5.9.2.1. FG-4592/Roxadustat (FibroGen)

5.9.2.2. Daprodustat/GSK1278863 (GlaxoSmithKline)

5.9.2.3. Molidustat/BAY85-3934 (Bayer)

5.9.2.4. MT-6548 (Mitsubishi Tanabe Pharma Corporation)

5.9.2.5. Rivipansel/GMI-1070 (Pfizer)

5.9.2.6. Luspatercept (Celgene)

5.9.2.7. AG-348 (Agios Pharmaceuticals, Inc.)

5.9.2.8. Sutimlimab (Bioverativ Therapeutics Inc.)

5.9.2.9. V114 (Merck Sharp & Dohme Corp.)

5.9.2.10. LentiGlobin/BB305 (bluebird bio)

5.9.2.11. APL-2 (Apellis Pharmaceuticals, Inc.)

5.9.2.12. ALXN1210 (Alexion Pharmaceuticals)

5.9.2.13. OMS721 (Omeros Corporation)

5.9.3. Phase II (Tabular Representation)

5.9.4. Phase I (Tabular Representation)

Chapter 6. Global Anemia Treatment Drugs Market, by Geography,
2016 – 2026 (US$ Mn)

6.1. Overview

6.2. North America Anemia Treatment Drugs Market Analysis, 2016 – 2026

6.3. Europe Anemia Treatment Drugs Market Analysis, 2016 – 2026

6.4. Asia Pacific Anemia Treatment Drugs Market Analysis, 2016 – 2026

6.5. Latin America Anemia Treatment Drugs Market Analysis, 2016 – 2026

6.6. Middle East & Africa (MEA) Anemia Treatment Drugs Market Analysis,
2016 – 2026

Chapter 7. Company Profiles

7.1. Amgen, Inc.

7.1.1. Business Description

7.1.2. Financial Information (Subject to data availability)

7.1.3. Product Portfolio

7.1.4. Key Developments

7.2. Hoffmann-La Roche Ltd.

7.3. Novartis AG

7.4. Pfizer, Inc.

7.5. Janssen Pharmaceuticals, Inc.

7.6. Teva Pharmaceutical Industries, Ltd.

7.7. AMAG Pharmaceuticals

7.8. Rockwell Medical

7.9. Akebia Therapeutics

7.10. Vifor Pharma Management, Ltd.

7.11. FibroGen, Inc.

7.12. GlaxoSmithKline plc

7.13. Bayer AG

7.14. Omeros Corporation

7.15. Merck Sharp & Dohme Corp.

For more information about this report visit https://www.researchandmarkets.com/r/c3ab0c

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs